TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06212388
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Study: NCT06631625
Drug: Lidocaine Intravenous Infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
Study: NCT06631625
Drug: Lidocaine and ketamine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
Study: NCT06631625
Drug: lidocaine and dexmedetomidine infusion
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
Study: NCT05926960
Drug: encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encorafenib
Study: NCT05926960
Drug: binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: binimetinib
Study: NCT05926960
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab
Study: NCT05926960
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab
Study: NCT05926960
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab
Study: NCT05905367
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
Study: NCT05905367
Drug: Slow-release oral morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
Study: NCT05788094
Drug: Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Study: NCT05788094
Drug: Chloroquine plus Tafenoquine (450 mg adult dose)
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Study: NCT05073237
Drug: conjugated estrogens/bazedoxifene (CE/BZA)
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.
Study: NCT04789850
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral for 360 days
Study: NCT04657991
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Encorafenib
Study: NCT04657991
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Binimetinib
Study: NCT04657991
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab
Study: NCT03553615
Drug: Ivermectin Pill
Normalized name: ivermectin Pill
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral anti-parasitic agent taken as a weekly dose for four weeks
Study: NCT05490030
Drug: TNO155
Normalized name: SHP2 inhibitor TNO155
DrugBank: Batoprotafib (DB19137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of TNO155 on Day 1
Study: NCT04891133
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg baricitinib (2 tablets of 2 mg) once daily
Study: NCT05920122
Drug: 2% Chlorhexidine gluconate with 70% alcohol
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
Study: NCT05920122
Drug: 4% Chlorhexidine Gluconate aqueous solution
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
Study: NCT06583590
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin (BoNT) is One of the most potent toxins known to humans produced by Clostridium botulinum that has been used to treat several striated and smooth muscle disorders. Because the pathophysiology and the reason for patients' lack of response to PDE5I is insufficient smooth muscle relaxation and veno-occlusive disorder (VOD) , BTX-A may prove to be a viable treatment for this patient population due to its availability to facilitate long-acting cavernosal smooth muscle relaxation by inhibition of the release of noradrenaline from the adrenergic neurons acting on the cavernosal smooth muscle. Thus, the dominant sympathetic basal tone of the cavernosal smooth muscle is essentially removed, facilitating the occurrence of an erection.
Study: NCT06583590
Drug: Tadalafil 5mg
Normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil is one of 5-phosphodiesterase inhibitors that used to treat male sexual function problems (impotence or erectile dysfunction-ED). In combination with sexual stimulation, tadalafil works by increasing blood flow to the penis to help a man get and keep an erection.Tadalafil is also used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tadalafil is thought to work by relaxing the smooth muscle in the prostate and bladder.
Study: NCT05039944
Drug: SI-B001
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
Study: NCT05039944
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration by intravenous infusion, 180 mg/m2 Q2W.
Study: NCT05886582
Drug: Rotigotine Transdermal System [Neupro]
Normalized name: rotigotine Transdermal System [Neupro]
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
Study: NCT04727320
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
Study: NCT05617651
Drug: IY-NT-T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 20mg
Study: NCT05020210
Drug: Sivelestat sodium
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
Study: NCT05868226
Drug: ALX148
Normalized name: Sirpa variant alx148
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
Study: NCT05868226
Drug: Fam-Trastuzumab Deruxtecan-Nxki
Normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
Study: NCT05868226
Drug: Zanidatamab
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
Study: NCT05868226
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
Study: NCT05391126
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Usual dosing per package insert.
Study: NCT05169424
Drug: Tiotropium + Olodaterol (5/5 mcg)
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium + Olodaterol (5/5 mcg)
Study: NCT05169424
Drug: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Normalized name: fluticasone furoate / umeclidinium / vilanterol Inhalant Product
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Study: NCT03400098
Drug: Inotersen
Normalized name: INOTERSEN
DrugBank: Inotersen (DB14713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
Study: NCT06176144
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.
Study: NCT06176144
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
Study: NCT06238115
Drug: Tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
Study: NCT06238115
Drug: aspirin, clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: aspirin 100 mg/day, clopidogrel 75 mg/day
Study: NCT04218539
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg Psilocybin
Study: NCT06548477
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
Study: NCT04589611
Drug: amobarbital/Gel-One (one dose)
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of amobarbital/Gel-One during the initial surgical intervention
Study: NCT04589611
Drug: amobarbital/Gel-One (two doses)
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Study: NCT04391309
Drug: remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
Study: NCT05803590
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the gold standard against which other anti-plaque and gingivitis agents are measured
Study: NCT05739123
Drug: Relugolix-Containing Product
Normalized name: Relugolix-containing product
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any relugolix-containing therapy
Study: NCT06217354
Drug: Carbetocin 100 Microgram/mL Solution for Injection
Normalized name: Carbetocin 100 microgram/mL solution for injection
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
Study: NCT05216237
Drug: Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
Study: NCT05906576
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab in the treatment of Crohn's disease in children
Study: NCT05964257
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Study: NCT06440850
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06440850
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05390307
Drug: Liraglutide / Semaglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
Study: NCT05390307
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 5-10 mg once daily for 6 months.
Study: NCT05390307
Drug: Liraglutide or Semaglutide / Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
Study: NCT05390307
Drug: Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
Study: NCT00939458
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05944237
Drug: HTL0039732 Capsules and atezolizumab infusion
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HTL0039732 Capsules will be administered orally on a QD schedule to fasted participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Cycle 1 will consist of HTL0039732 monotherapy. From Cycle 2 onwards, participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.
Study: NCT05576662
Drug: Nirmatrelvir
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two 150 mg tablets taken by mouth every 12 hours
Study: NCT05576662
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 100 mg capsule taken by mouth every 12 hours
Study: NCT05203913
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
Study: NCT05203913
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
Study: NCT05203913
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
Study: NCT06196606
Drug: Botulinum toxin type A for injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin was injected into the upper esophageal sphincter of each patient
Study: NCT06335316
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
Study: NCT00000821
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05001204
Drug: 68Ga-NOTA-RM26
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
Study: NCT05892913
Drug: Slow dose preemptive Atropine
Normalized name: Slow-Fe
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
Study: NCT05892913
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For sympathetic blockade (SBP\<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
Study: NCT06413238
Drug: curcumin, saffron, Combination of saffron and curcumin and placebo
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
Study: NCT04971356
Drug: Aspirin 100mg for 1-month (immediately after PCI)
Normalized name: aspirin 100 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm